Loading organizations...
§ Private Profile · Seoul, Seoul-t'ukpyolsi, South Korea
Biotech company developing therapeutics and platforms for neurodegenerative and immune diseases, focused on CNS.
Illimis Therapeutics, based in Seoul, Korea, with a secondary office in Boston, USA, develops chimeric fusion proteins and proprietary platform technologies to treat neurodegenerative and immune-related diseases. The company leverages its GAIA (Gas6-mediated Anti-Inflammatory Adaptor) platform, focusing on central nervous system (CNS) and immune disease therapeutics for conditions like Alzheimer's disease. It has secured total funding between $57.2 million and $66.4 million, reporting annual revenue of $2,053,320 and an estimated valuation of $6.6 million, with 21-50 employees. Illimis maintains a partnership with Eli Lilly through their Catalyze360-ExploR&D program. CEO Sanghoon Park and scientific co-founders Wonsuk Chung and Chanhyuk Kim founded the organization in 2021. Its business model centers on venture-backed biotech company funded through Series B financing and government grants, maintains partnership with Eli Lilly through their Catalyze360-ExploR&D program for co-development efforts.
Illimis Therapeutics has raised $41.8M across 1 funding round.
Illimis Therapeutics has raised $41.8M in total across 1 funding round.
Illimis Therapeutics has raised $41.8M across 1 funding round. Most recently, it raised $41.8M Series B in July 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 14, 2025 | $41.8M Series B | Yohan KIM | AJU IB Investment, A Ventures, Company K Partners, Daily Partners, GS Ventures, Hana Ventures, IMM Investment, Industrial Bank OF Korea, Korea Development Bank, LB Investment, Maple Investment Partners, Quad Investment Management, Schmidt, Shinhan Venture Investment, S&S Investment, TS Investment, Jiwoong Chun | Announced |
Illimis Therapeutics has raised $41.8M in total across 1 funding round.
Illimis Therapeutics's investors include Yohan Kim, AJU IB Investment, A Ventures, Company K Partners, Daily Partners, GS Ventures, Hana Ventures, IMM Investment, Industrial Bank of Korea, Korea Development Bank, LB Investment, Maple Investment Partners.